Clinical trials: Catecholamines
Catecholamine Resistant Hypotension (CRH), Distributive Shock
Expanded Access for LJPC-501
The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.
- Conditions
- Catecholamine Resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- NCT03245528
- Testing
- LJPC-501
- Sponsor
- La Jolla Pharmaceutical Company
Hypertension
Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension
This study compares the effect of Adalat LA to Coracten on drug levels as well as changes in blood pressure and heart rate in fed hypertensive subjects.
- Trial name
- NCT00672113
- Testing
- Adalat (Nifedipine, BAYA1040), Coracten
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- Bayer
Vasodilatory Shock
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
A randomized, double-blind, placebo-controlled study on the treatment of refractory distributed shock with angiotensin II injection, with a random ratio of 1:1.
- Trial name
- NCT06351150
- Testing
- Angiotensin II Injection, 0.9% sodium chloride injection
- Where
- 42 sites in China
- Volunteers
- 214 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Catecholamine-resistant Hypotension (CRH), Distributive Shock
A Study of LJPC-501 in Pediatric Patients With Hypotension
The objective of this study is to evaluate the effect of LJPC-501 infusion on mean arterial pressure (MAP) or reduction in sum norepinephrine (NE) equivalent dosing, at Hour 2 after the start of LJPC-501, in pediatric patients…
- Conditions
- Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- NCT03431077
- Testing
- Angiotensin II
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- La Jolla Pharmaceutical Company
Catecholamine-resistant Hypotension (CRH), Distributive Shock
A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock
The objective of this study is to evaluate the effect of LJPC-501 infusion on mean arterial pressure (MAP) as assessed by standard of care vasopressor dose reduction in pediatric patients with catecholamine-resistant hypotension…
- Conditions
- Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Septic Shock
- Trial name
- NCT03623529
- Testing
- LJPC-501 (angiotensin II)
- Where
- 2 sites in Belgium, Lithuania
- Volunteers
- 100 people
- Sponsor
- La Jolla Pharmaceutical Company
Catecholamine-resistant Hypotension (CRH), Distributive Shock
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple centers globally.
- Conditions
- Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- ATHOS-3 (NCT02338843)
- Testing
- LJPC-501
- Where
- 115 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- La Jolla Pharmaceutical Company